Market Cap 44.34B
Revenue (ttm) 21.84B
Net Income (ttm) 1.68B
EPS (ttm) N/A
PE Ratio 11.18
Forward PE 12.39
Profit Margin 7.68%
Debt to Equity Ratio 0.67
Volume 2,660,100
Avg Vol 2,919,482
Day's Range N/A - N/A
Shares Out 284.74M
Stochastic %K 42%
Beta 0.29
Analysts Sell
Price Target $188.25

Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 201 847 6800
Website: www.bd.com
Address:
1 Becton Drive, Franklin Lakes, United States
SuperGreenToday
SuperGreenToday Apr. 14 at 3:37 AM
$BDX Share Price: $155.37 Contract Selected: Sep 18, 2026 $155 Calls Buy Zone: $8.50 – $10.50 Target Zone: $13.99 – $17.10 Potential Upside: 55% ROI Time to Expiration: 157 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
erevnon
erevnon Apr. 10 at 7:54 PM
Goldman Sachs reinstates Becton Dickinson $BDX at Neutral and announces a price target of https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
TalkMarkets
TalkMarkets Apr. 8 at 6:55 PM
10 Bargain #Dividend #Stocks For Value And Income $BDX $BR $CDW $CI $HRL https://talkmarkets.com/article/10-bargain-dividend-stocks-for-value-and-income-1775673044
0 · Reply
TalkMarkets
TalkMarkets Apr. 7 at 9:13 PM
Top 10 Bear Market #Stocks For Reliable Dividends $ABT $GPC $SYY $PEP $BDX https://talkmarkets.com/article/f2aee3e0-5b47-4ae7-9176-06f875ebbbd8
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 1 at 3:44 PM
$BDX Share Price: $156.49 Contract Selected: Sep 18, 2026 $155 Calls Buy Zone: $25.50 – $31.50 Target Zone: $46.49 – $56.82 Potential Upside: 72% ROI Time to Expiration: 169 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
SparkyReturns
SparkyReturns Mar. 26 at 4:39 PM
1 · Reply
SparkyReturns
SparkyReturns Mar. 25 at 2:40 PM
$AMGN I like AMGN and other big biotechs long term, but wanted to alert you of a company reporting ER and pivotal news after close TODAY. Tiny company (ICU) has the first meaningful improvement in treating Acute Kidney Injury in decades. Already being used with children, and adults soon (50x market size). $9 Million MC, with a TAM in the Billions (read that again). 90% margins. Ramping up product which will become Standard of Care for a number of conditions involving hyper-inflammation and sepsis (AKI, Cardiorenal, burn victims, transplant patients, COVID/respiratory). Saves lives of AKI patients and ELIMINATES dialysis dependency. Total addressable market 2B-20B. Zero debt. Ample runway. Pivotal adult AKI study to be completed in 9 months. Being used at Mayo Clinic, Cinci Childrens, UCSF, Dallas Childrens, dozens more hospitals. 6 (SIX!) Breakthrough Device Designations. So, 9M MC for a company that will be worth Billions in a few years. $BDX $PFE $MRNA $TAK
0 · Reply
anachartanalyst
anachartanalyst Mar. 23 at 4:02 PM
$BDX https://anachart.com/wp-content/uploads/ana_temp/1774281700_soc-img.jpg
0 · Reply
STACKD0E
STACKD0E Mar. 23 at 2:55 PM
$BDX 🙃✨
0 · Reply
11thestate
11thestate Mar. 23 at 1:14 PM
With everything going on around $BDX lately — this is the info you don't want to miss: https://11th.com/cases/bdx-shareholder-settlement
0 · Reply
Latest News on BDX
Rick Byrd to Retire from BD

Apr 9, 2026, 4:05 PM EDT - 6 days ago

Rick Byrd to Retire from BD


Lanesha Minnix Named General Counsel for BD

Feb 19, 2026, 4:15 PM EST - 7 weeks ago

Lanesha Minnix Named General Counsel for BD


What's Going On With Becton Dickinson Stock Tuesday?

Feb 10, 2026, 2:17 PM EST - 2 months ago

What's Going On With Becton Dickinson Stock Tuesday?


Dow Falls 250 Points; Becton Dickinson Posts Upbeat Earnings

Feb 9, 2026, 10:01 AM EST - 2 months ago

Dow Falls 250 Points; Becton Dickinson Posts Upbeat Earnings


BD Reports First Quarter Fiscal 2026 Financial Results

Feb 9, 2026, 6:30 AM EST - 2 months ago

BD Reports First Quarter Fiscal 2026 Financial Results


BD To Host Virtual 2026 Annual Meeting of Shareholders

Jan 12, 2026, 4:15 PM EST - 3 months ago

BD To Host Virtual 2026 Annual Meeting of Shareholders


SuperGreenToday
SuperGreenToday Apr. 14 at 3:37 AM
$BDX Share Price: $155.37 Contract Selected: Sep 18, 2026 $155 Calls Buy Zone: $8.50 – $10.50 Target Zone: $13.99 – $17.10 Potential Upside: 55% ROI Time to Expiration: 157 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
erevnon
erevnon Apr. 10 at 7:54 PM
Goldman Sachs reinstates Becton Dickinson $BDX at Neutral and announces a price target of https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
TalkMarkets
TalkMarkets Apr. 8 at 6:55 PM
10 Bargain #Dividend #Stocks For Value And Income $BDX $BR $CDW $CI $HRL https://talkmarkets.com/article/10-bargain-dividend-stocks-for-value-and-income-1775673044
0 · Reply
TalkMarkets
TalkMarkets Apr. 7 at 9:13 PM
Top 10 Bear Market #Stocks For Reliable Dividends $ABT $GPC $SYY $PEP $BDX https://talkmarkets.com/article/f2aee3e0-5b47-4ae7-9176-06f875ebbbd8
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 1 at 3:44 PM
$BDX Share Price: $156.49 Contract Selected: Sep 18, 2026 $155 Calls Buy Zone: $25.50 – $31.50 Target Zone: $46.49 – $56.82 Potential Upside: 72% ROI Time to Expiration: 169 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
SparkyReturns
SparkyReturns Mar. 26 at 4:39 PM
1 · Reply
SparkyReturns
SparkyReturns Mar. 25 at 2:40 PM
$AMGN I like AMGN and other big biotechs long term, but wanted to alert you of a company reporting ER and pivotal news after close TODAY. Tiny company (ICU) has the first meaningful improvement in treating Acute Kidney Injury in decades. Already being used with children, and adults soon (50x market size). $9 Million MC, with a TAM in the Billions (read that again). 90% margins. Ramping up product which will become Standard of Care for a number of conditions involving hyper-inflammation and sepsis (AKI, Cardiorenal, burn victims, transplant patients, COVID/respiratory). Saves lives of AKI patients and ELIMINATES dialysis dependency. Total addressable market 2B-20B. Zero debt. Ample runway. Pivotal adult AKI study to be completed in 9 months. Being used at Mayo Clinic, Cinci Childrens, UCSF, Dallas Childrens, dozens more hospitals. 6 (SIX!) Breakthrough Device Designations. So, 9M MC for a company that will be worth Billions in a few years. $BDX $PFE $MRNA $TAK
0 · Reply
anachartanalyst
anachartanalyst Mar. 23 at 4:02 PM
$BDX https://anachart.com/wp-content/uploads/ana_temp/1774281700_soc-img.jpg
0 · Reply
STACKD0E
STACKD0E Mar. 23 at 2:55 PM
$BDX 🙃✨
0 · Reply
11thestate
11thestate Mar. 23 at 1:14 PM
With everything going on around $BDX lately — this is the info you don't want to miss: https://11th.com/cases/bdx-shareholder-settlement
0 · Reply
TalkMarkets
TalkMarkets Mar. 21 at 1:48 AM
Healthcare Sector Review : Q1 2026 Cutbacks In Government Spending Are Taking Its Toll $ABOS $ABT $AXSM $BBIO $BDX https://talkmarkets.com/article/healthcare-sector-review-q1-2026-cutbacks-in-government-spending-are-taking-its-toll-1774057180
0 · Reply
11thestate
11thestate Mar. 9 at 12:30 PM
If you missed the deadline, don’t miss this update. This is probably the most useful info you’ve read in years about $BDX — how you can actually recover something: https://11th.com/cases/bdx-shareholder-settlement
0 · Reply
ZacksResearch
ZacksResearch Mar. 6 at 6:47 PM
$BDX shares have plunged 11.3% over the past six months despite new CE Mark approval for Revello stent — are investors missing the potential? 🤔 🔍 CE Mark strengthens BD’s footing in the growing PAD market 📈 Expanding minimally invasive vascular solutions could boost long-term growth in a market projected to grow at a CAGR of 7.56% Opportunity assessment here 👉 https://www.zacks.com/stock/news/2880337/bdx-secures-ce-mark-for-revello-stent-to-treat-iliac-artery-disease?cid=sm-stocktwits-2-2880337-body-36467&ADID=SYND_STOCKTWITS_TWEET_2_2880337_BODY_36467
0 · Reply
ZacksResearch
ZacksResearch Mar. 6 at 5:47 PM
$BDX just scored a key regulatory win in vascular treatment. The company secured CE Mark for its Revello vascular covered stent designed to treat iliac artery disease, expanding its peripheral vascular portfolio in the growing PAD treatment market. 🩺 See why this development matters for the stock 👉 https://www.zacks.com/stock/news/2880337/bdx-secures-ce-mark-for-revello-stent-to-treat-iliac-artery-disease?cid=sm-stocktwits-2-2880337-teaser-36407&ADID=SYND_STOCKTWITS_TWEET_2_2880337_TEASER_36407
0 · Reply
ZacksResearch
ZacksResearch Mar. 5 at 6:53 PM
$BDX just secured a new FDA clearance — expanding its surgical toolkit. The company received FDA 510(k) clearance for the Surgiphor 1000mL antimicrobial irrigation system, adding a powered lavage option to its surgical irrigation portfolio. 🏥 See what this approval could mean for the business 👉 https://www.zacks.com/stock/news/2879660/bd-gains-fda-clearance-for-surgiphor-1000ml-surgical-irrigation-system?cid=sm-stocktwits-2-2879660-teaser-36241&ADID=SYND_STOCKTWITS_TWEET_2_2879660_TEASER_36241
0 · Reply
ZacksResearch
ZacksResearch Mar. 5 at 5:53 PM
$BDX gets FDA clearance for Surgiphor 1000mL — but shares have lost 1.6% since Monday! 🤔 The new antimicrobial irrigation system aims to enhance surgical efficiency and patient care, yet shares have slid 10.9% over the past six months, underperforming its industry and the S&P 500. Discover the potential long-term impact for BDX 👉 https://www.zacks.com/stock/news/2879660/bd-gains-fda-clearance-for-surgiphor-1000ml-surgical-irrigation-system?cid=sm-stocktwits-2-2879660-body-36229&ADID=SYND_STOCKTWITS_TWEET_2_2879660_BODY_36229
0 · Reply
11thestate
11thestate Feb. 26 at 2:59 PM
$BDX investors, if you follow us, you already know about it. This info hits different after the news. Check it out: https://11th.com/cases/bdx-shareholder-settlement
0 · Reply
ZacksResearch
ZacksResearch Feb. 24 at 6:04 PM
$BDX just upgraded a routine test — and it’s smarter than it sounds. 🧪 The new three-tube Urine Complete Cup Kit expands testing from a single sample, aiming to boost lab efficiency and reduce contamination risks. That’s workflow improvement + accuracy in one move. Incremental innovation… or a quiet margin lever? See what this could mean for the bigger picture 👉 https://www.zacks.com/stock/news/2874553/bd-launches-urine-complete-cup-kit-for-smarter-testing-accuracy?cid=sm-stocktwits-2-2874553-teaser-34977&ADID=SYND_STOCKTWITS_TWEET_2_2874553_TEASER_34977
0 · Reply
ZacksResearch
ZacksResearch Feb. 24 at 5:04 PM
$BDX launches innovative urine collection kit — but shares dip. What’s up? 🤔 Despite launching the BD Vacutainer Urine Complete Cup Kit to enhance diagnostic testing and improve lab efficiency, BDX shares fell 0.6% yesterday. Over the past six months, the stock has declined 5.3%, underperforming the industry’s 22.3% growth. Currently, BDX holds a Zacks Rank #5 (Strong Sell). Discover the full story and potential implications here 👉 https://www.zacks.com/stock/news/2874553/bd-launches-urine-complete-cup-kit-for-smarter-testing-accuracy?cid=sm-stocktwits-2-2874553-body-34942&ADID=SYND_STOCKTWITS_TWEET_2_2874553_BODY_34942
0 · Reply
11thestate
11thestate Feb. 17 at 1:46 PM
$BDX has agreed to settle with investors over claims that it misled them about the functionality, safety, and regulatory status of its Alaris infusion pump system. Who’s eligible? Anyone who purchased $BDX shares between November 5, 2019 and February 5, 2020. Do I need to sell my shares to qualify? No — you are eligible whether you sold your shares or still hold them. How much is the payout? The payout per share is $2.14 — but normally only ~25% of eligible investors file, the effective payout could increase to $8.56. Can I still file? Yes — late claims are currently being considered for compensation, subject to approval. When do payouts happen? Typically within 8–12 months after court approval of the settlement. To file your claim: https://11th.com/cases/bdx-shareholder-settlement
0 · Reply
ZacksResearch
ZacksResearch Feb. 11 at 7:01 PM
$BDX just reshaped its future — and walked away with $4B in the process. 💰 The company completed its Biosciences & Diagnostic spin-off and merger with Waters, locking in $4B in proceeds as it pivots to a pure-play MedTech focus. That’s a major strategic reset. See what this transformation means for shareholders 👉 https://www.zacks.com/stock/news/2855593/bd-merges-biosciences-diagnostics-business-with-waters?cid=sm-stocktwits-2-2855593-teaser-33195&ADID=SYND_STOCKTWITS_TWEET_2_2855593_TEASER_33195
0 · Reply